Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Inclocibart (BAY 3018250) in Healthy Chinese Participants
NCT06619483Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of inclocibart in thrombosis and thromboembolism (3 arms), sponsored by Bayer. Primary endpoint: Number of participants who experienced treatment-emergent adverse events. Started Oct 2024; status: completed.
02
Drugs
inclocibart
03
Conditions
thrombosisthromboembolism
Beyond the preview
Go deeper on NCT06619483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619483.